Anti-Aging Therapeutics Market, 2022-2040
The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society.Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. , Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans. ,
Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. ,Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term.
SCOPE OF THE REPORT
The “Anti-aging Therapeutics Market - Distribution by Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others) and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2040” report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:
- A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates).
- A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).
- An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations.
- A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations.
- An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis.
- A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published).
- A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
- Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
- Peter Fedichev (Co-Founder and Chief Executive Officer, Gero.AI)
- James Clement (President, Betterhumans)
- Wee Kiat Tan (Chief Operating Officer, CytoMed Therapeutics)
- Rosa Argyropoulos (Senior Director of Global Corporate Communications, Cambrian Biopharma)
- Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist, Landmark Medical Centre)
Anti-aging Therapeutics: Market Segmentations
Market Segments Details
Forecast Period
- 2022 - 2040
- Biologics
- Small Molecules
- Cellular Aging
- Immune Aging
- Metabolic Aging
- Others
- North America
- Europe
- Asia Pacific
- Rest of the World
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views
KEY QUESTIONS ANSWERED
- Who are the leading players engaged in the development of anti-aging therapeutics?
- What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?
- Who are the key investors in the anti-aging therapeutics domain?
- How is the intellectual property landscape in this field likely to evolve in the foreseen future?
- What is the evolving trend of publications focused on anti-aging therapeutics?
- What are the key value drivers that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of anti-aging therapeutics market and its likely evolution in the short term, mid-term and long term.
Chapter 3 provides a general introduction to the aging process. In addition, the chapter features information on the types and causes of aging. It also presents an elaborate description of the mechanism of action adopted by anti-aging therapeutics. Further, it highlights various diseases related to aging, as well as discusses the key facts and future perspectives associated with anti-aging therapeutics.
Chapter 4 features a detailed review of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mTOR inhibitor / modulator, AMP-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter presents analysis related to anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates).
Chapter 5 presents a detailed competitiveness analysis of anti-aging therapeutics developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).
Chapter 6 provides an elaborate discussion and analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, in the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (research and development agreements, product / technology licensing agreements, research agreements, acquisitions, mergers and joint ventures), most active player(s) (in terms of number of partnerships inked), type of partner and regional distribution (continent and country-wise) of collaborations.
Chapter 7 provides details on the various investments and grants that have been awarded to players focused on the development of anti-aging therapeutics. It includes a detailed analysis of the funding instances that have taken place during the period 2018-2022, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
Chapter 8 presents an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, patent focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 9 consists of a detailed analysis of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publishers, most popular journals, most popular affiliations and most popular funding institutes (in terms of number of articles published).
Chapter 10 provides insights on a qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
Chapter 11 includes brief profiles of prominent players engaged in the development of anti-aging therapeutics. Each profile features a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
Chapter 12 features an elaborate discussion on the future commercial opportunity offered by anti-aging therapeutics. It provides a comprehensive market forecast analysis for molecules that are in phase II and above development stages taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapeutics. The chapter also presents a detailed market segmentation on the basis of [A] type of molecule (biologics and small molecules), [B] type of aging (cellular aging, immune aging, metabolic aging and others), and [C] key geographies (North America, Europe, Asia Pacific, and Rest of the world).
Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Peter Fedichev (Co-Founder and Chief Executive Officer, Gero.AI), James Clement (President, Betterhumans), Wee Kiat Tan (Chief Operating Officer, CytoMed Therapeutics), Rosa Argyropoulos (Senior Director of Global Corporate Communications, Cambrian Biopharma) and Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist, Landmark Medical Centre).
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.
- 1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
- 2. EXECUTIVE SUMMARY
- 3. INTRODUCTION
- 3.1. Overview of Aging
- 3.2. Types of Aging
- 3.3. Causes of Aging
- 3.4 Mechanism of Action of Anti-aging Therapeutics
- 3.5 Age-related Diseases
- 3.6 Key Facts Associated with Aging
- 3.7 Future Perspectives of Anti-aging Therapeutics
- 4. MARKET LANDSCAPE
- 4.1. Anti-aging Therapeutics: Overall Market Landscape
- 4.1.1. Analysis by Phase of Development
- 4.1.2. Analysis by Type of Aging
- 4.1.3. Analysis by Phase of Development and Type of Aging
- 4.1.4. Analysis by Type of Molecule
- 4.1.5. Analysis by Mechanism of Action
- 4.1.6. Analysis by Type of Developers
- 4.2. Anti-aging Therapeutics: Developer Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size and Location of Headquarters
- 4.2.3. Leading Developers by Number of Therapeutics
- 4.2.4. Regional Landscape of Developers
- 5. COMPANY COMPETITIVENESS ANALYSIS
- 5.1. Chapter Overview
- 5.2. Assumptions and Key Parameters
- 5.3. Methodology
- 5.4. Anti-aging Therapeutics: Company Competitiveness Analysis
- 5.4.1. Small Companies
- 5.4.2. Mid-sized and Large Companies
- 6. PARTNERSHIPS AND COLLABORATIONS
- 6.1. Chapter Overview
- 6.2. Anti-aging Therapeutics: Partnerships and Collaborations
- 6.2.1 Analysis by Year of Partnership
- 6.2.2. Analysis by Type of Partnership
- 6.2.3. Analysis by Year and Type of Partnership
- 6.2.4. Leading Players: Analysis by Number of Partnerships
- 6.2.5. Analysis by Type of Partner
- 6.2.6. Analysis by Type of Agreement
- 6.2.7. Analysis by Region
- 6.2.7.1. Intercontinental and Intracontinental Deals
- 6.2.7.2. International and Local Deals
- 7. FUNDING AND INVESTMENTS
- 7.1. Chapter Overview
- 7.2. Anti-aging Therapeutics: Funding and Investments
- 7.2.1. Analysis of Instances by Year
- 7.2.2. Analysis of Amount Invested by Year
- 7.2.3 Analysis of Instances by Type of Funding
- 7.2.4. Analysis of Amount Invested by Type of Funding
- 7.2.5. Analysis by Type of Investor
- 7.2.6. Analysis by Focus Area
- 7.2.7. Analysis of Amount Invested by Region
- 7.2.8. Analysis of Amount Invested by Country
- 7.2.9. Most Active Investors: Analysis by Number of Instances
- 7.2.10. Most Active Players: Analysis by Number of Instances
- 7.2.11. Most Active Players: Analysis by Amount Invested
- 8. PATENT ANALYSIS
- 8.1. Chapter Overview
- 8.2. Scope and Methodology
- 8.3. Anti-aging Therapeutics: Patent Analysis
- 8.3.1. Analysis by Type of Patent
- 8.3.2. Analysis by Patent Publication Year
- 8.3.3. Analysis of Granted Patents by Year
- 8.3.4. Analysis by Geography
- 8.3.5. Analysis by CPC Symbols
- 8.3.6. Analysis by Type of Applicant
- 8.3.7. Analysis by Emerging Focus Areas
- 8.3.8. Analysis by Patent Age
- 8.3.9. Leading Industry Players: Analysis by Number of Patents
- 8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
- 8.3.11. Leading Individual Assignees: Analysis by Number of Patents
- 8.4. Anti-aging Therapeutics: Patent Benchmarking
- 8.4.1. Analysis by Patent Characteristics
- 8.5. Anti-aging Therapeutics: Patent Valuation
- 9. PUBLICATION ANALYSIS
- 9.1. Chapter Overview
- 9.2. Scope and Methodology
- 9.3. Anti-aging Therapeutics: Publication Analysis
- 9.3.1. Analysis by Year of Publication
- 9.3.2. Analysis by Type of Publication
- 9.3.3. Most Popular Journals: Analysis by Number of Publications
- 9.3.4. Most Popular Journals: Analysis by Impact Factor
- 9.3.5. Analysis by Most Popular Keywords
- 9.3.6. Most Popular Funding Institutes: Analysis by Number of Publications
- 9.3.7. Most Active Publisher: Analysis by Number of Publications
- 9.3.8. Most Popular Affiliation: Analysis by Number of Publications
- 9.3.9. Analysis by Geography
- 10. PORTER’S FIVE FORCES ANALYSIS
- 10.1. Chapter Overview
- 10.2. Methodology and Key Parameters
- 10.3. Porter’s Five Forces
- 10.3.1. Threat of New Entrants
- 10.3.2. Bargaining Power of End Users
- 10.3.3. Bargaining Power of Drug Developers
- 10.3.4. Threat of Substitute Products
- 10.3.5. Rivalry Among Existing Competitors
- 11. COMPANY PROFILES
- 11.1. AgelessRx
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.3. Recent Developments and Future Outlook
- 11.2. ANOVA Institute for Regenerative Medicine
- 11.2.1. Company Overview
- 11.2.2. Product Portfolio
- 11.2.3. Recent Developments and Future Outlook
- 11.3. Betterhumans
- 11.3.1. Company Overview
- 11.3.2. Product Portfolio
- 11.3.3. Recent Developments and Future Outlook
- 11.4. BioAge Labs
- 11.4.1. Company Overview
- 11.4.2. Product Portfolio
- 11.4.3. Recent Developments and Future Outlook
- 11.5. bioXcellerator
- 11.5.1. Company Overview
- 11.5.2. Product Portfolio
- 11.5.3. Recent Developments and Future Outlook
- 11.6. Cambrian Biopharma
- 11.6.1. Company Overview
- 11.6.2. Product Portfolio
- 11.6.3. Recent Developments and Future Outlook
- 11.7. Gero.ai
- 11.7.1. Company Overview
- 11.7.2. Product Portfolio
- 11.7.3. Recent Developments and Future Outlook
- 11.8. Mayo Clinic
- 11.8.1. Company Overview
- 11.8.2. Product Portfolio
- 11.8.3. Recent Developments and Future Outlook
- 11.9. Rejuvenate Bio
- 11.9.1. Company Overview
- 11.9.2. Product Portfolio
- 11.9.3. Recent Developments and Future Outlook
- 11.10. UT Health San Antonio
- 11.10.1. Company Overview
- 11.10.2. Product Portfolio
- 11.10.3. Recent Developments and Future Outlook
- 12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
- 12.1. Forecast Methodology and Key Assumptions
- 12.2. Global Anti-aging Therapeutics Market, 2022-2040
- 12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule
- 12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging
- 12.2.3. Anti-aging Therapeutics Market: Analysis by Geography
- 12.2.3.1. Anti-aging Therapeutics Market in North America, 2022-2040
- 12.2.3.2. Anti-aging Therapeutics Market in Europe, 2022-2040
- 12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific, 2022-2040
- 12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040
- 12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales
- 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues
- 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues
- 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues
- 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues
- 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues
- 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues
- 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues
- 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues
- 13. EXECUTIVE INSIGHTS
- 13.1. Chapter Overview
- 13.2. Gero.ai
- 13.2.1 Company Snapshot
- 13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer)
- 13.3. Betterhumans
- 13.3.1. Company Snapshot
- 13.3.2. Interview Transcript: James Clement (President)
- 13.4. CytoMed Therapeutics
- 13.4.1. Company Snapshot
- 13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer)
- 13.5. Cambrian Biopharma
- 13.5.1 Company Snapshot
- 13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications)
- 13.6. Landmark Medical Centre
- 13.6.1 Company Snapshot
- 13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist)
- 14. APPENDIX I: TABULATED DATA
- 15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS
- LIST OF FIGURES
- Figure 2.1 Executive Summary: Overall Market Landscape
- Figure 2.2 Executive Summary: Partnerships and Collaborations
- Figure 2.3 Executive Summary: Funding and Investment Analysis
- Figure 2.4 Executive Summary: Patent Analysis
- Figure 2.5 Executive Summary: Publication Analysis
- Figure 2.6 Executive Summary: Market Forecast
- Figure 3.1 Types of Aging
- Figure 3.2 Causes of Aging
- Figure 3.3 Mechanism of Action of Anti-aging Therapeutics
- Figure 3.4 Age-related Diseases
- Figure 4.1 Anti-aging Therapeutics: Distribution by Phase of Development
- Figure 4.2 Anti-aging Therapeutics: Distribution by Type of Aging
- Figure 4.3 Anti-aging Therapeutics: Distribution by Phase of Development and Type of Aging
- Figure 4.4 Anti-aging Therapeutics: Distribution by Type of Molecule
- Figure 4.5 Anti-aging Therapeutics: Distribution by Mechanism of Action
- Figure 4.6 Anti-aging Therapeutics Developers: Distribution by Type of Developers
- Figure 4.7 Anti-aging Therapeutics Developers: Distribution by Year of Establishment
- Figure 4.8 Anti-aging Therapeutics Developers: Distribution by Company Size and Location of Headquarters
- Figure 4.9 Leading Developers: Distribution by Number of Therapeutics
- Figure 4.10 Anti-aging Therapeutics Developers: Regional Landscape
- Figure 5.1 Company Competitiveness Analysis: Small Companies
- Figure 5.2 Company Competitiveness Analysis: Mid-sized and Large Companies
- Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
- Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Figure 6.4 Leading Players: Distribution by Number of Partnerships
- Figure 6.5 Partnerships and Collaborations: Distribution by Type of Partner
- Figure 6.6 Partnerships and Collaborations: Distribution by Type of Agreement
- Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
- Figure 6.8 Partnerships and Collaborations: International and Local Deals
- Figure 7.1 Funding and Investments: Distribution of Instances by Year
- Figure 7.2 Funding and Investments: Distribution of Amount Invested by Year
- Figure 7.3 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
- Figure 7.4 Funding and Investments: Distribution of Instances by Type of Funding
- Figure 7.5 Funding and Investments: Distribution of Amount Invested by Type of Funding
- Figure 7.6 Funding and Investments: Distribution by Type of Investor
- Figure 7.7 Funding and Investments: Distribution by Focus Area
- Figure 7.8 Funding and Investments: Distribution of Amount Invested by Region
- Figure 7.9 Funding and Investments: Distribution of Amount Invested by Country
- Figure 7.10 Most Active Investors: Distribution by Number of Instances
- Figure 7.11 Most Active Players: Distribution by Number of Instances
- Figure 7.12 Most Active Players: Distribution by Amount Invested
- Figure 8.1 Patent Analysis: Distribution by Type of Patent
- Figure 8.2 Patent Analysis: Distribution by Patent Publication Year
- Figure 8.3 Patent Analysis: Distribution of Granted Patents by Year
- Figure 8.4 Patent Analysis: Distribution by Geography
- Figure 8.5 Patent Analysis: Distribution by CPC Symbols
- Figure 8.6 Patent Analysis: Distribution by Type of Applicant
- Figure 8.7 Patent Analysis: Emerging Focus Area
- Figure 8.8 Patent Analysis: Distribution by Patent Age
- Figure 8.9 Leading Industry Players: Distribution by Number of Patents
- Figure 8.10 Leading Non-Industry Players: Distribution by Number of Patents
- Figure 8.11 Leading Individual Assignees: Distribution by Number of Patents
- Figure 8.12 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
- Figure 8.13 Anti-aging Therapeutics: Patent Valuation
- Figure 9.1 Publication Analysis: Distribution by Year of Publication
- Figure 9.2 Publication Analysis: Distribution by Type of Publication
- Figure 9.3 Most Popular Journals: Distribution by Number of Publications
- Figure 9.4 Most Popular Journals: Distribution by Impact Factor
- Figure 9.5 Publication Analysis: Most Popular Keywords
- Figure 9.6 Most Popular Funding Institutes: Distribution by Number of Publications
- Figure 9.7 Most Active Publisher: Distribution by Number of Publications
- Figure 9.8 Most Popular Affiliation: Distribution by Number of Publications
- Figure 9.9 Publication Analysis: Distribution by Geography
- Figure 10.1 Anti-aging Therapeutics: Porter’s Five Forces Analysis
- Figure 12.1 Global Anti-aging Therapeutics Market, 2035-2040 (USD Million)
- Figure 12.2 Anti-aging Therapeutics Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
- Figure 12.3 Anti-aging Therapeutics Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
- Figure 12.4 Anti-aging Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
- Figure 12.5 Anti-aging Therapeutics Market in North America, 2022-2040 (USD Million)
- Figure 12.6 Anti-aging Therapeutics Market in Europe, 2022-2040 (USD Million)
- Figure 12.7 Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 (USD Million)
- Figure 12.8 Anti-aging Therapeutics Market in Rest of the World, 2022-2040 (USD Million)
- Figure 12.9 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.10 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.11 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.12 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.13 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.14 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.15 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Figure 12.16 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- LIST OF TABLES
- Table 4.1 List of Anti-aging Therapeutics
- Table 4.2 List of Anti-aging Therapeutics Developers
- Table 6.1 Anti-aging Therapeutics: List of Partnerships and Collaborations
- Table 7.1 Anti-aging Therapeutics: List of Funding and Investments
- Table 8.1 Anti-aging Therapeutics: List of Patents
- Table 8.2 Patent Analysis: Categorization based on Weighted Valuation Scores
- Table 9.1 Anti-aging Therapeutics: List of Publications
- Table 11.1 AgelessRx: Product Portfolio
- Table 11.2 AgelessRx: Recent Developments and Future Outlook
- Table 11.3 ANOVA Institute for Regenerative Medicine: Product Portfolio
- Table 11.4 Betterhumans: Product Portfolio
- Table 11.5 Betterhumans: Recent Developments and Future Outlook
- Table 11.6 BioAge Labs: Product Portfolio
- Table 11.7 BioAge Labs: Recent Developments and Future Outlook
- Table 11.8 bioXcellerator: Product Portfolio
- Table 11.9 Cambrian Biopharma: Product Portfolio
- Table 11.10 Cambrian Biopharma: Recent Developments and Future Outlook
- Table 11.11 Gero.ai: Product Portfolio
- Table 11.12 Gero.ai: Recent Developments and Future Outlook
- Table 11.13 Mayo Clinic: Product Portfolio
- Table 11.14 Mayo Clinic: Recent Developments and Future Outlook
- Table 11.15 Rejuvenate Bio: Product Portfolio
- Table 11.16 Rejuvenate Bio: Recent Developments and Future Outlook
- Table 11.17 UT Health San Antonio: Product Portfolio
- Table 11.18 UT Health San Antonio: Recent Developments and Future Outlook
- Table 14.1 Market Landscape: Distribution by Phase of Development
- Table 14.2 Market Landscape: Distribution by Type of Aging
- Table 14.3 Market Landscape: Distribution by Phase of Development and Type of Aging
- Table 14.4 Market Landscape: Distribution by Type of Molecule
- Table 14.5 Market Landscape: Distribution by Mechanism of Action
- Table 14.6 Developer Landscape: Distribution by Type of Developers
- Table 14.7 Developer Landscape: Distribution by Year of Establishment
- Table 14.8 Developer Landscape: Distribution by Company Size and Location of Headquarters
- Table 14.9 Leading Developers: Distribution by Number of Therapeutics
- Table 14.10 Partnerships and Collaborations: Distribution by Year of Partnership
- Table 14.11 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 14.12 Partnerships and Collaborations: Distribution by Year and Type of Partnership
- Table 14.13 Leading Players: Distribution by Number of Partnerships
- Table 14.14 Partnerships and Collaborations: Distribution by Type of Partner
- Table 14.15 Partnerships and Collaborations: Distribution by Type of Agreement
- Table 14.16 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
- Table 14.17 Partnerships and Collaborations: International and Local Deals
- Table 14.18 Funding and Investments: Distribution of Instances by Year
- Table 14.19 Funding and Investments: Distribution of Amount Invested by Year
- Table 14.20 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding
- Table 14.21 Funding and Investments: Distribution of Instances by Type of Funding
- Table 14.22 Funding and Investments: Distribution of Amount Invested by Type of Funding
- Table 14.23 Funding and Investments: Distribution by Type of Investor
- Table 14.24 Funding and Investments: Distribution by Focus Area
- Table 14.25 Funding and Investments: Distribution of Amount Invested by Region
- Table 14.26 Funding and Investments: Distribution of Amount Invested by Country
- Table 14.27 Most Active Investors: Distribution by Number of Instances
- Table 14.28 Most Active Players: Distribution by Number of Instances
- Table 14.29 Most Active Players: Distribution by Amount Invested
- Table 14.30 Patent Analysis: Distribution by Type of Patent
- Table 14.31 Patent Analysis: Distribution by Patent Publication Year
- Table 14.32 Patent Analysis: Distribution of Granted Patents by Year
- Table 14.33 Patent Analysis: Distribution by Geography
- Table 14.34 Patent Analysis: Distribution by Type of Applicant
- Table 14.35 Patent Analysis: Distribution by Patent Age
- Table 14.36 Leading Industry Players: Distribution by Number of Patents
- Table 14.37 Leading Non-Industry Players: Distribution by Number of Patents
- Table 14.38 Leading Individual Assignees: Distribution by Number of Patents
- Table 14.39 Anti-aging Therapeutics: Patent Valuation
- Table 14.40 Publication Analysis: Distribution by Year of Publication
- Table 14.41 Publication Analysis: Distribution by Type of Publication
- Table 14.42 Most Popular Journals: Distribution by Number of Publications
- Table 14.43 Most Popular Journals: Distribution by Impact Factor
- Table 14.44 Most Popular Funding Institutes: Distribution by Number of Publications
- Table 14.45 Most Active Publisher: Distribution by Number of Publications
- Table 14.46 Most Popular Affiliation: Distribution by Number of Publications
- Table 14.47 Publication Analysis: Distribution by Geography
- Table 14.48 Global Anti-aging Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2035-2040 (USD Million)
- Table 14.49 Anti-aging Therapeutics Market: Distribution by Type of Molecule, 2022 and 2040 (USD Million)
- Table 14.50 Anti-aging Therapeutics Market: Distribution by Type of Aging, 2022 and 2040 (USD Million)
- Table 14.51 Anti-aging Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
- Table 14.52 Anti-aging Therapeutics Market in North America, 2022-2040 (USD Million)
- Table 14.53 Anti-aging Therapeutics Market in Europe, 2022-2040 (USD Million)
- Table 14.54 Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 (USD Million)
- Table 14.55 Anti-aging Therapeutics Market in Rest of the World, 2022-2040 (USD Million)
- Table 14.56 bioXgel (PRP) (bioXcellerator): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.57 AR-100 (Rejenevie Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.58 BGE-117 (BioAge Labs): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.59 Dasatinib and Quercetin (TruDiagnostic): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.60 MYMD-1 (MyMD Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.61 TRIIM Treatment (Intervene Immune): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.62 Rapamycin (AgelessRx): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- Table 14.63 Sarconeos (BIO101) (Biophytis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2040 (USD Million)
- LIST OF COMPANIES AND ORGANIZATIONS
- The following companies and organizations have been mentioned in the report.
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook